- Home
- GF vs RNAC Comparison
GF vs RNAC Comparison
Compare GF & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GF | RNAC |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 168.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | GF | RNAC |
|---|---|---|
| Price | $11.47 | $6.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 51.7K | ★ 163.7K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.98 | $5.60 |
| 52 Week High | $12.82 | $14.56 |
Technical Indicators
Market Signals| Indicator | GF | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 54.89 |
| Support Level | $11.26 | $6.54 |
| Resistance Level | $11.71 | $7.67 |
| Average True Range (ATR) | 0.28 | 0.48 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 31.90 | 69.88 |
Price Performance
Historical ComparisonAbout GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.